Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oramed Pharmaceuticals, a developer of oral delivery systems, has reported that it will start a Phase IIb clinical trial on 30 type 2 diabetic volunteers. This study is intended to evaluate the safety, tolerability and efficacy of its oral insulin capsule ORMD-0801.
Subscribe to our email newsletter
This Phase IIb trial is an important milestone for Oramed as it will test its first indication for ORMD-0801 on a large group of volunteers for the duration of six weeks. This six week randomized, double blind placebo controlled study will be performed in three locations in Cape Town, South Africa.
OnQ Consulting, a clinical research organization located in Johannesburg, South Africa, will oversee the clinical trials.
Nadav Kidron, CEO of Oramed, said: “We are pleased to begin this study of ORMD-0801 on type 2 diabetes patients following our successful Phase IIa clinical trials in August 2008.”